Yi Wang, Yuxi Zhang, Haoyi Sun, Jilan Chen, Hui Yang, Zhanqiong Zhong, Xiaoqian Xiao, Yanping Li, Yibei Tang, Haolan Lu, Xinzhi Tang, Mengyang Zhang, Wenjun Wu, Shiyi Zhou, Jiahui Yang
Over the last decade, immuno-oncologic drugs especially CD3-engaging bispecific antibodies (biAbs) are experiencing fast-paced evolution, but big challenges still exist in the clinical development of biAbs in solid tumors, especially non-small cell lung cancer (NSCLC). In this study, we choose a ROR1 × CD3 biAb in scFv-Fc format, named R11 × v9 biAb, to investigate its tumor-inhibiting role in NSCLC. Notably, the ROR1-engaging arm binds both human and mouse ROR1. We found that R11 × v9 biAb specifically binds T cells and tumor cells simultaneously, and dose-dependent cytotoxicity was detected for various ROR1+ NSCLC cell lines...
July 25, 2023: International Immunopharmacology